Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05298592 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | PHASE1 | COMPLETED | 77 | — | — | Mar 31, 2022 | Aug 16, 2024 | Sep 26, 2024 | 29 | United States, Argentina +4 |
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986406 (Monotherapy Dose Escalation) | EXPERIMENTAL | - |
| Part 1B: BMS-986406 + Nivolumab (Combination Dose Escalation) | EXPERIMENTAL | - |
| Part 1C: BMS-986406 + Nivolumab (Indication-Specific Dose Expansion) | EXPERIMENTAL | - |
| Part 2: BMS-986406 + Nivolumab (Expansion Cohorts) | EXPERIMENTAL | - |
| Part 1D: BMS-986406 + Nivolumab + Carboplatin with Pemetrexed or Paclitaxel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986406 | BIOLOGICAL | Specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
| Carboplatin | DRUG | Specified dose on specified days |
| Pemetrexed | DRUG | Specified dose on specified days |
| Paclitaxel | DRUG | Specified dose on specified days |
Inclusion Criteria: Parts 1A, 1B, 1C: * Histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent malignant tumor. Eligible tumor types are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |